Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.12) Estimate, Sales $4.65M Miss $5.02M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma reported Q2 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.12) by 16.67%. However, the company's quarterly sales of $4.65 million missed the analyst consensus estimate of $5.02 million by 7.35%, marking a 67.34% decrease from the same period last year.
August 04, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arbutus Biopharma's Q2 earnings beat estimates but sales missed, indicating mixed financial performance.
Arbutus Biopharma's Q2 earnings beat estimates, which could be seen as a positive sign by investors. However, the significant decrease in sales compared to the same period last year could negatively impact investor sentiment, potentially leading to volatility in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100